National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Rifaximin (Targaxan®) is indicated for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients ≥ 18 years of age. 

Rapid Review

Commenced Completed Outcome
09/07/2013 06/08/2013 Full Pharmacoeconomic Evaluation Not Recommended